I'm LongbridgeAI, I can summarize articles.Elevance Health reported strong Q2 earnings, beating estimates with $7.45 adjusted EPS and $49.83 billion revenue, while raising full-year guidance. Following the announcement, analysts revised price targets: Baird raised to $393, Guggenheim raised to $455, and Barclays lowered to $457, though ratings remained largely unchanged.
Elevance Health Inc. (NYSE:ELV) on Wednesday reported upbeat second-quarter results and raised its full-year guidance.
Adjusted earnings came in at $7.45 per share, beating the analyst consensus estimate of $6.21. Revenue rose to $49.83 billion, above the consensus estimate of $48.69 billion.
Elevance now expects fiscal 2026 adjusted earnings of at least $27 per share, up from prior guidance of at least $26.75 and above the Wall Street consensus estimate of $26.91. The company also raised its fiscal 2026 operating cash flow forecast to at least $6 billion.
Elevance Health shares rose 1.8% to $397.20 in pre-market trading.
These analysts made changes to their price targets on Elevance Health following earnings announcement.
- Baird analyst Michael Ha maintained the stock with a Neutral and raised the price target from $331 to $393.
- Barclays analyst Andrew Mok maintained Elevance Health with an Overweight rating and lowered the price target from $480 to $457.
- Guggenheim analyst Jason Cassorla maintained the stock with a Buy and raised the price target from $399 to $455.
Considering buying ELV stock? Here’s what analysts think:
Photo via Shutterstock